A5057281435- Childhood Cancer Survivors' Quality of Life
- Acute Lymphoblastic Leukemia research
- Sarcoma Diagnosis and Treatment
- Family Support in Illness
- Cancer, Lipids, and Metabolism
- Palliative Care and End-of-Life Issues
- Cancer, Hypoxia, and Metabolism
- Adolescent and Pediatric Healthcare
- Neuroblastoma Research and Treatments
- Lymphoma Diagnosis and Treatment
- Cancer survivorship and care
- Testicular diseases and treatments
- Glioma Diagnosis and Treatment
- Radiomics and Machine Learning in Medical Imaging
- Cardiac tumors and thrombi
- Renal and related cancers
- BRCA gene mutations in cancer
- Ethics and Legal Issues in Pediatric Healthcare
- Cancer Genomics and Diagnostics
- Bone health and osteoporosis research
- Vitamin D Research Studies
- Bone health and treatments
- Chemotherapy-induced cardiotoxicity and mitigation
- Autopsy Techniques and Outcomes
- Reproductive Biology and Fertility
Skåne University Hospital
2016-2025
Lund University
2016-2025
Getinge (Sweden)
2016-2022
Clinical Orthopaedics and Related Research
2019
Princess Máxima Center
2016-2018
Royal Hospital for Sick Children
2018
Royal Hospital for Children
2018
Tel Aviv Sourasky Medical Center
2018
Support group for adolescents and children with cancer
2018
Sydney Children's Hospital
2018
To improve the poor prognosis of patients with primary disseminated multifocal Ewing sarcomas (PDMES) a dose-intense treatment concept.From 1999 to 2005, 281 PDMES were enrolled onto Euro-EWING 99 R3 study. Median age was 16.2 years (range, 0.4 49 years). Recommended consisted six cycles vincristine, ifosfamide, doxorubicin, and etoposide (VIDE), one cycle dactinomycin, ifosfamide (VAI), local (surgery and/or radiotherapy), high-dose busulfan-melphalan followed by autologous stem-cell...
1. Eleven patients with the bone loss of ageing were treated vitamin D analogue 1 alpha-hydroxycholecalciferol and calcium for 3--6 months. 2. Muscle biopsies taken from vastus lateralis before after treatment activity several enzymes was measured. Succinate dehydrogenase total phosphorylase activities, which are a measure oxidative capacity, low increased significantly treatment. The lactate activity, can be as anaerobic metabolism, normal did not change phosphagen stores, ATP creatine...
Relative efficacy and toxicity of cyclophosphamide compared with ifosfamide are debatable. The Euro-EWING99-R1 trial asked whether may replace in combination vincristine dactinomycin (vincristine, dactinomycin, [VAC] v vincristine, [VAI]) after an intensive induction chemotherapy containing ifosfamide, doxorubicin, etoposide (VIDE) standard-risk localized disease (NCT00020566).
Purpose For over 30 years, the place of consolidation high-dose chemotherapy in Ewing sarcoma (ES) has been controversial. A randomized study was conducted to determine whether improved survival patients with localized ES at high risk for relapse. Methods Randomization between busulfan and melphalan (BuMel) or standard (vincristine, dactinomycin, ifosfamide [VAI], seven courses) offered if they were younger than 50 years age poor histologic response (≥ 10% viable cells) after receiving...
With the advent of multimodality therapy, overall five-year survival rate from childhood cancer has improved considerably now exceeding 80% in developed European countries. This growing cohort survivors, with many years life ahead them, raised necessity for knowledge concerning risks adverse long-term sequelae life-saving treatments order to provide optimal screening and care identify adequate interventions. Childhood survivor cohorts Europe. Considerable advantages exist study late effects...
PURPOSE The R2Pulm trial was conducted to evaluate the effect of busulfan-melphalan high-dose chemotherapy with autologous stem-cell rescue (BuMel) without whole-lung irradiation (WLI) on event-free survival (main end point) and overall survival, compared standard WLI in Ewing sarcoma (ES) presenting pulmonary and/or pleural metastases. METHODS From 2000 2015, we enrolled patients younger than 50 years age newly diagnosed ES only or Patients received six courses vincristine, ifosfamide,...
BackgroundCurrently, there are between 300,000 and 500,000 childhood cancer survivors (CCSs) in Europe. A significant proportion is at high risk, least 60% of them develop adverse health-related outcomes that can appear several years after treatment completion. Many unaware their personal seems to be a general lack information among healthcare providers about pathophysiology natural history treatment-related complications. This generate incorrect or delayed diagnosis treatments.MethodThe...
Background: Long-term follow-up (LTFU) care for childhood, adolescent, and young adult (CAYA) cancer survivors is essential to preserve health quality of life (QoL).Evidence-based guidelines are needed inform optimal surveillance strategies, but many topics yet be addressed by the International Late Effects Childhood Cancer Guideline Harmonization Group (IGHG).Therefore, PanCareFollowUp Recommendations Working collaborated with stakeholders develop European harmonised recommendations in...
Abstract A method for thyroid volume calculation based upon ultrasonic scanning is described. The accuracy of the was estimated by comparing ultrasonically determined volumes with surgically removed glands. precision (i.e., reproducibility) two separate investigators in a double blind fashion. normal range evaluated group volunteers. acceptable, but borderline and appears to be limiting factor procedure. We concluded that at present this offers no significant improvement over other methods...
Over 14 000 patients aged 15-24 are estimated to be diagnosed with cancer in the European Union (EU) each year. Teenagers and young adults (TYA) often fall down gaps between children's services. The specific challenges of providing optimal care them described, but we present a summary recent progress. Progress overcome these is happening at different rates across Europe. We summarise national projects this field more recently have seen beginnings coordination. Within EU 7th Funding Programme...
Ewing 2008R3 was conducted in 12 countries and evaluated the effect of treosulfan melphalan high-dose chemotherapy (TreoMel-HDT) followed by reinfusion autologous hematopoietic stem cells on event-free survival (EFS) overall high-risk sarcoma (EWS).Phase III, open-label, prospective, multicenter, randomized controlled clinical trial. Eligible patients had disseminated EWS with metastases to bone and/or other sites, excluding only pulmonary metastases. Patients received six cycles...
Abstract Background Fatigue is prevalent in adult cancer survivors but less studied childhood survivors. Aims were to assess fatigue levels, prevalence of chronic (CF) and the association CF with health‐related quality life (HRQoL) acute myeloid leukemia (AML), infratentorial astrocytoma (IA), Wilms tumor (WT) childhood. Procedure Seventy percent (398/567) Nordic patients treated for AML, IA, WT between 1985 2001 at age >1 year responded a postal survey, encompassing Questionnaire Short...
NK cells are an important component of host immune defense against malignancy and infection. educated by MHC class I ligands to ensure self-tolerance while also promoting lytic competency altered self damaged targets. However, the intracellular molecular events that culminate in tolerance functional remain undefined. Mice with germline deficiency SHIP1 were shown have a defective cell compartment. is expressed all hematopoietic lineages, consequently several hematolymphoid phenotypes already...
Abstract Background Local treatment of pelvic Ewing’s sarcoma may be challenging, and intergroup studies have focused on improving systemic treatments rather than prospectively evaluating aspects local tumor control. The Euro-EWING99 trial provided a substantial number patients with localized tumors treated the same chemotherapy protocol. Because control included surgical resection, radiation therapy, or combination both, we wanted to investigate survival respect modality in this study...
Childhood cancer survivors face risks from a variety of late effects, including cardiac events, second cancers, and mortality. The aim the pan-European PanCare Adolescent Cancer Survivor Care Follow-Up Studies (PanCareSurFup) Consortium was to collect data on incidence risk factors for these effects among childhood in Europe. This paper describes methodology collection overall PanCareSurFup cohort outcome-related cohorts. In 13 providers 12 countries delivered centre Mainz. Data used single...